Olympus 2008 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2008 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

> In the Others business, Olympus mainly engages in
the manufacture and sale of industrial endoscopes,
non-destructive testing devices, printers and bar code
scanners, as well as system development.
Sales in the Others business rose 7.6% year on year to
¥69,259 million (US$660 million), and operating income
climbed 5.2% to ¥917 million (US$9 million).
Olympus is reinforcing its lineup of industrial
endoscopes and non-destructive testing devices that
provide optimal solutions for various industrial inspec-
tion needs. Sales of portable flaw detectors and highly
functional ultrasonic phased-array instruments were
particularly robust. In the remote visual inspection field,
sales of the new IPLEX FX portable industrial videoscope
with high durability, functionality and resolution
expanded, contributed to the revenue increase.
In the domestic information equipment field, Olympus
saw an increase in shipments of printers and printer
components manufactured in collaboration with Riso
Kagaku Corporation.
In the biomedical materials field, Olympus estab-
lished Olympus Terumo Biomaterials Corp. jointly with
Terumo Corporation in April 2007. During the fiscal year
under review, Olympus also commenced full-scale
overseas sales of OSferion bone replacement material
and the marketing of collagen-related products contain-
ing Terudermis, an artificial dermal graft material used
3.
BONE REPLACEMENT
MATERIAL
OSferion 60
This artificial bone
replacement material
contains β-tricalcium
phosphate for enhanced
mechanical strength.
to treat serious dermal and mucosal defects, as well as
Teruplug. These achievements resulted in the substan-
tial revenue increase.
An increase in overall sales was recorded in the
Others business, reflecting ITX Corporation’s growth in
medical-related businesses, including new business
acquisitions. As a result, Olympus recorded increased
earnings.
OUTLOOK FOR
FISCAL 2009
> Olympus is forecasting an increase in revenue on the
back of steady growth in the sale of non-destructive
testing devices, including industrial endoscopes, as well
as in the printer business. Against the backdrop of an
ongoing trend of a stronger yen and increasing invest-
ment in product development, however, earnings are
expected to decline. Overall, Olympus anticipates sales
of ¥70 billion and an operating loss of ¥8.0 billion.
2.
PHASED-ARRAY
INSTRUMENT
OmniScan
MX PA
A high-speed data collection
rate and powerful software
features contribute to
efficient manual and
automated inspections.
Others
OTHERS BUSINESS
Sales
(Millions of yen)
07
Overseas
sales
Domestic
sales
08
35,908
33,351
69,259
64,377
32,372
32,005
I Communication Business, and Others
OLYMPUS 2008 19